$VXRT Vaxart has been in the spotlight this year following its efforts to develop an oral tablet vaccine against the deadly coronavirus disease. Last month, Vaxart’s oral COVID-19 vaccine candidate was selected for investigation in a non-human primate challenge study. The new study will be organized and funded by Operation Warp Speed (“OWS”), which is a new national program, to provide substantial quantities of safe, effective vaccine for Americans by January 2021. The company plans to start a phase I study on the oral tablet vaccine candidate in the second half of this year. Shares of the company have skyrocketed more than 4200% so far this year. VAXART, INC. Price VAXART, INC. Price
  • 3